한빛사 논문
Abstract
Beomseok Suh1,†, Sehhoon Park2,†, Dong Wook Shin1,3,*, Jae Moon Yun1, Hyung-Kook Yang4, Su Jong Yu5, Cheong-Il Shin6, Jin-Soo Kim7, Eunmi Ahn1, Hyejin Lee1,3, Jin Ho Park1 and BeLong Cho1,3
1 Department of Family Medicine & Health Promotion Center, Seoul National University Hospital, Seoul, Republic of Korea
2 Department of Internal Medicine, Division of Hematology & Medical Oncology, Seoul National University Hospital, Seoul, Republic of Korea
3 Cancer Survivorship Clinic, Seoul National University Cancer Hospital, Seoul, Republic of Korea
4 Cancer Policy Branch, National Cancer Control Institute, National Cancer Center, Goyang, Republic of Korea
5 Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
6 Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea
7 Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Republic of Korea
† These authors contributed equally.
*CORRESPONDING AUTHOR: Dong Wook Shin, M.D., Dr.P.H., M.B.A., Department of Family Medicine & Health Promotion Center, Seoul National University Hospital, Cancer Survivorship Clinic, Seoul National University Cancer Hospital, 101 Daehakro, Jongnogu, Seoul 110-744, Republic of Korea,
ABSTRACT
Screening for hepatocellular carcinoma (HCC) is clinically important as its early detection has remarkable survival benefits. We investigated the possible role of FIB-4, a recently developed noninvasive marker for liver fibrosis based on routine laboratory tests, as a clinical indicator for predicting future HCC among hepatitis B surface antigen (HBsAg) carriers. Our retrospective cohort study involved 986 Korean HBsAg carriers aged 40 or older who visited Seoul National University Hospital for health check-up. National medical service claims data was used to determine HCC incidence. Median follow-up time was 5.4 years (interquartile range 4.4 years). Adjusted for age, sex, body mass index, smoking, alcohol, and anti-viral medication for hepatitis B, compared to subjects with FIB-4 <1.25, subjects with 1.7≤ FIB-4 <2.4 showed aHR 4.57 (95% CI 1.50-13.92) and subjects with FIB-4 ≥2.4 showed aHR 21.34 (95% CI 7.73-58.92) for HCC incidence. FIB-4 was shown to have incremental predictive value to ultrasonographic liver cirrhosis for HCC incidence (C-index 0.701 vs. 0.831; P=0.001). FIB-4 was also better predictive of HCC incidence compared to that of ultrasonographic liver cirrhosis (C-index 0.775 vs. 0.701; P=0.040). Conclusion: High FIB-4 is a highly predictive risk factor for HCC incidence among Korean HBsAg carriers. FIB-4 is a promising, easily applicable, and cost-effective clinical tool in identifying a subpopulation of HBsAg carriers who are at heightened risk. Our study needs to be replicated in larger future studies on various ethnic groups; nonetheless, our study suggests FIB-4 may play a valuable role in HCC screening among HBsAg carriers. This article is protected by copyright. All rights reserved.
Keywords:hepatitis B virus; liver cirrhosis; liver fibrosis; cancer screening
논문정보
관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기